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Background: One third of patients with infective endocarditis will require operative intervention. Given the
superiority of valve repair over valve replacement in many indications other than endocarditis, there has been
increasing interest and an increasing number of reports of excellent results of valve repair in acute infective
endocarditis. The theoretically ideal material for valve repair in this setting is non-permanent, “vanishing” material,
not at risk of seeding or colonization. The goal of this contribution is to review currently available data on
biodegradable materials for valve repair in infective endocarditis.
Discussion: Rigorous electronic and manual literature searches were conducted to identify reports of
biodegradable materials for valve repair in infective endocarditis. Articles were identified in electronic database
searches of Medline, Embase and the Cochrane Library, using a predetermined search strategy. 49 manuscripts
were included in the review. Prosthetic materials needed for valve repair can be summarized into annuloplasty
rings to remodel the mitral or tricuspid annulus, and patch materials to replace resected valvar tissue. The
commercially available biodegradable annuloplasty ring has shown interesting clinical results in a single-center
experience; however further data is required for validation and longer follow-up. Unmodified extra-cellular matrix
patches, such as small intestinal submucosa, have had promising initial experimental and clinical results in
non-infected valve repair, although in valve repair for endocarditis has been reported in only one patient, and
concerns have been raised regarding their mechanical stability in an infected field.
Summary: These evolving biodegradable devices offer the potential for valve repair with degradable materials
replaced with autologous tissue, which could further improve the results of valve repair for infective endocarditis.
This is an evolving field with promising experimental or initial clinical results, however long-term outcomes are
lacking and further data is necessary to validate this theoretically interesting approach to infective endocarditis.
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Infective endocarditis is a serious disease with an inci-
dence of 30 to 100 per million patient-years [1-3]. Mortal-
ity is high: more than a third of patients will die within the
first year of diagnosis [4,5]. The role of surgery in the
treatment of infective endocarditis has been expanding,
and current guidelines advocate surgical management for
complicated infective endocarditis [6,7]; approximately
one third of patients with infective endocarditis will* Correspondence: patrick.myers@hcuge.ch
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unless otherwise stated.require operative intervention [8]. Early surgery is strongly
indicated for patients with infective endocarditis and con-
gestive heart failure, large left-sided vegetations (>10 mm)
at high risk of embolism, persistent or locally uncontrolled
infection (abscess, false aneurysm, fistula or enlarging
vegetation), varying between a recommendation of class I
to IIa and a level of evidence of B to C [5].
Operative principles for infective endocarditis include
complete debridement of infected tissues, drainage of
abscess cavities followed by restoration of anatomic re-
lationships, such as ventriculo-aortic or atrioventricular
continuity [9]. Several surgical options exist to restore a
competent valve depending on the extent of valvetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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Figure 1 Degradation and fibrous tissue deposition after
biodegradable annuloplasty implantation (reproduced with
permission from Kalangos et al [26]).
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repair to valve replacement. Valve replacement with an
off-the shelf prosthetic valve in the setting of active infec-
tion can lead to recurrent infection, estimated between 2%
to 9% [9,10]. Infection-resistant prosthetic valves have
been developed, however their results are poor and no
devices are currently approved for clinical use. The multi-
center prospective randomized Artificial Valve Endocardi-
tis Reduction Trial (AVERT), using a prosthetic valve
made with a silver Silzone-coated sewing cuff, was
stopped before completion due to a higher rate of major
paravalvular leaks requiring reoperation [11]. Other mo-
dalities, such as biodegradable matrices that secrete anti-
bacterial proteins [12], are still at the stage of basic
research and have yet to be tested in clinical settings. Ho-
mografts have been advanced as an ideal substitute in the
setting of active endocarditis due to their biological nature
and absence of foreign woven material, although they re-
main susceptible to recurrent infection [13] and compli-
cate the initial and subsequent valve replacements.
Given the superiority of valve repair over valve re-
placement in many indications [14,15] other than endo-
carditis, there has been increasing interest and an
increasing number of reports of excellent results of valve
repair in acute infective endocarditis [16].
Discussion
Rationale for Biodegradable Materials in Infective
Endocarditis
Monofilament suture has been shown to be less suscep-
tible to colonization in in vitro and in vivo laboratory
studies compared to braided multifilament suture [17-20].
However, in the setting of an infected surgical field which
requires placement of foreign material to perform the
planned operation, the theoretically ideal material is non-
permanent, “vanishing” material [21], dissolving and to be
replaced by autologous tissue. The prosthetic materials
needed for valve repair can be summarized into annulo-
plasty rings to remodel the mitral or tricuspid annulus,
and patch materials to replace resected valvar tissue.
With the use of adapted perioperative antibiotics and
complete surgical debridement, the rate of recurrent
endocarditis is, as mentioned previously, quite low both
in valve repair and replacement. This implies that any
study looking at these technologies, beyond the “proof
of concept” phase, will need a large number of patients
and rigorous follow-up to have sufficient power to see if
these new biodegradable materials can do better than
conventional techniques.
Biodegradable Annuloplasty
It is tempting to avoid an annuloplasty ring when fixing
limited leaflet destruction from mitral or tricuspid valve
infective endocarditis [22], under the assumption that theunderlying mechanism is acute regurgitation and usually
doesn’t involve annular dilatation. Annuloplasty plays an
important role in valve reconstruction, particularly if a sig-
nificant infected leaflet segment must be resected, to re-
lieve tension on the repaired leaflets and ensure long-term
stability of the repair. Traditional annuloplasty rings and
bands, predominantly made of polyester mesh, are suscep-
tible to seeding and infection. Ciprofloxacin-coated poly-
ester annuloplasty ring mesh was shown to confer
infection resistance in a subcutaneous animal implant-
ation model [23], however these devices haven’t been re-
ported in clinical use to date.
Temporary annuloplasty with a biodegradable device
replaced with autologous fibrous tissue would theoretic-
ally reduce the risk of infection recurrence and durably
remodel the annulus. Duran et al. reported the results of
DeVega annuloplasty using 2–0 polydioxanone suture in
an experimental sheep model [24], as well as their clin-
ical results in 73 patients with functional tricuspid regur-
gitation [25], showing that this provided temporary
“vanishing” annuloplasty that stabilizes the annulus for
4 months. There has been no further follow-up data
from this patient cohort, and no similar reports beyond
functional tricuspid regurgitation.
The Bioring Kalangos® annuloplasty ring (formerly Bior-
ing SA, Lonay, Switzerland) was developed to extend the
annular stabilization beyond this time period, while
remaining biodegradable. It is a curved “C” segment of
poly-1,4-dioxanone polymer located on a non-degradable
polyvinyl monofilament suture equipped with a stainless
steel needle at each extremity. This ring is inserted suben-
docardially directly into the mitral or tricuspid annulus,
away from blood contact. In a juvenile pig model [26], it
was shown to dissolve in 6 months and be replaced at
12 months by autologous fibrous tissue (see Figure 1). The
close proximity of important structures to the posterior
mitral annulus, such as the circumflex coronary artery
and the great cardiac vein, has raised questions regarding
the safety of implanting the ring into the native annulus.
This issue was addressed by Cikirikcioglu et al. in a
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the ring and the circumflex coronary artery was 7.2 ±
2.7 mm, 11.0 ± 2.4 mm, and 10.7 ± 3.8 mm at the level of
anterolateral commissure, the mid posterior annulus, and
the posteromedial commissure, respectively [27].
Clinical results have been reported in children with
rheumatic mitral regurgitation [28], congenital mitral
[29,30] and tricuspid [31] regurgitation. The results have
been positive so far, with evidence of durable stabilization
of the mitral or tricuspid annulus while allowing for
growth in this pediatric patient population, as evidenced
by stable annular diameter Z-scores. Panos et al. also re-
ported the ease of implantation of this ring in minimally
invasive thoracoscopic or robotic mitral and tricuspid
valve repair [32]. Finally, Pektok et al. reported the histo-
logical findings 21 months after implantation in an adult
patient with ischemic mitral regurgitation, confirming that
the ring is degraded and replaced by dense autologous fi-
brous tissue along the posterior mitral annulus [33].
The infection resistance of the biodegradable annulo-
plasty ring was tested in an in vivo rat animal model
study, compared to the Carpentier-Edwards (Edwards
Lifesciences Corp, Irvine, CA, USA) Physio II ring (M.
Cikirikcioglu, personal communication, presented at
AATS mitral conclave 2013, poster E57: “infection resist-
ance testing of biodegradable annuloplasty ring in a rat
subcutaneous implantation model”). In this study,
segments of annuloplasty ring were implanted subcuta-
neously and topically inoculated with 2×107 colony
forming units (CFU) of Staphylococcus aureus. Cultures
of explanted rings were more frequently positive in con-
ventional rings (11/16) than the biodegradable ring
(2/16, P = 0.003), and the amount of growing bacteria
was also significantly increased in conventional rings
(7175 ± 5936 CFU/ml vs. 181 ± 130 CFU/ml in the bio-
degradable ring, P = 0.0005).
Clinical use of the biodegradable ring has been re-
ported for valve repair in infective endocarditis by Kazaz
et al. [34] and by our group [35,36]. From 2004 to 2009,
we implanted the ring in 17 patients with acute infective
endocarditis, 13 in the mitral, 3 in the tricuspid and 1 in
both valves [35]. There were 3 early deaths, and no late
evidence of endocarditis recurrence, valve dysfunction,
reoperations or deaths at a mean follow-up of 30 months.
We updated this report with our experience in 8 chil-
dren with infective endocarditis [36]. There were no
early or late deaths, reoperations or evidence of endocar-
ditis recurrence at a mean follow-up of 56 months.
These different studies are limited for the most part by
the fact that most data originated from our group (and
are currently being validated by more widespread use of
these devices) and a follow-up that extends to a max-
imum of 9 years now. This data represents little more
than a “proof of concept”, providing data on our initialfavorable experience, and mandates larger multi-center
prospective randomized studies to validate these initial
findings made in selected patients in a the hands of ded-
icated team.
Biodegradable Patches
Surgical management of infective endocarditis entails
debridement of all infected tissue, which may include
leaflets, the annulus or structures beyond the annulus
(such as the atrioventricular groove or the ventriculo-
arterial continuity), which require reconstruction. There
is relatively little data on leaflet patch reconstruction in
infective endocarditis, beyond a few limited case reports
or series. More generally in leaflet repair, all available
patch materials have disappointing mid- and long-term
results. Autologous fresh pericardium retracts with time,
while glutaraldehyde-fixed pericardium calcifies [37]. Ex-
panded polytetrafluoroethylene has been proposed as a
leaflet repair patch material [38], however mid- and
long-term follow-up data is still pending and this mater-
ial may be at risk of calcification [39] or late fracture
[40]. Each of these materials are permanent, non-
degradable and at risk of seeding and the cause of recur-
rent infection.
Given the poor long-term results of leaflet patch aug-
mentation overall (and not just in the setting of infective
endocarditis), new patch materials are being developed
to realize the dream of in vivo valvulogenesis, using
scaffolds intended to be colonized and replaced by
autologous tissue. Several synthetic scaffolds have been
proposed in vitro and in animal models, such as poly-
diaxonone [41], polyglycolic acid, poly–L-lactic acid [42]
or polyurethane. Their clinical application as a bio-
degradable patch for valve repair remains to be reported.
Biological scaffolds have also been developed, predom-
inantly using extracellular matrix (ECM). The structural
and functional components of ECM are transient, due to
the rapid rate of degradation of ECM scaffolds in vivo
[43]; they could be considered as temporary controlled
release vehicles for naturally occurring growth factors.
The characteristic of the intact ECM that distinguishes it
from other scaffold materials is its diversity of structural
proteins and associated bioactive molecules and their
unique spatial distribution. ECM can be harvested for
use as a therapeutic scaffold from the dermis, sub-
mucosa of the small intestine and urinary bladder,
pericardium, basement membrane and stroma of the
decellularized liver, and the decellularized Achilles ten-
don [43] (see Figure 2). Although there is abundant lit-
erature on modified ECM as a scaffold (e.g. in biological
prosthetic heart valves or glutaraldehyde-treated pericar-
dium), the data is newer on ECM that hasn’t been modi-
fied, except for decellularlization and sterilization. As
reviewed in detail by Badylak [43], ECM scaffolds that
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host response that promotes cell infiltration and rapid
scaffold degradation, deposition of host derived neoma-
trix and constructive tissue remodeling with minimal
scar tissue; this represents a fundamentally different
scaffold material than ECM that has been chemically or
otherwise modified.
CorMatrix© is a commercially available ECM scaffold
made of non-modified small intestinal submucosa. Ini-
tially approved for pericardial replacement, its use has
been expanded as a patch for intracardiac [44] and vas-
cular reconstruction [45]. Its application in heart valve
repair is relatively new, and there is a paucity of data
available. In a retrospective study of 25 children with
congenital mitral or tricuspid lesions who underwent
leaflet patch augmentation with CorMatrix©, the reoper-
ation rate was similar to matched controls who had
leaflet patch augmentation with glutaraldehyde-treated
pericardium at 12 months follow-up, although the
mechanism of failure tended to differ, with more patch
retractions in the pericardium group [46]. None of these
patients were operated on in the setting of acute infect-
ive endocarditis. There is only one report of CorMatrix©
use in infective endocarditis [47], reporting posterior mi-
tral leaflet augmentation with CorMatrix© for mitral
valve S. viridans endocarditis in one patient, and previ-
ously repaired ventricular septal defect patch replace-
ment with CorMatrix© for S. aureus septal patch
endocarditis and aortic root abscess. Both these patients
had favorable outcomes, with local (gentamycin fleece
left in situ around an aortic root graft) and systemic
adapted antibiotics, although follow-up was limited to
34 days and 3 months, respectively in each patient.
Although these biodegradable materials have promis-
ing initial experimental and clinical results in non-
infected valve repair, as well as theoretical advantages in
an infected surgical field, there are limited reports ofFigure 2 ECM harvested from porcine urinary bladder. This thin
(60 uM) sheet of ECM is entirely free of any cellular component, has
a multidirectional tensile strength of approximately 40 N, and has
not been chemically cross linked or modified from its native
structure. Reproduced with permission from Badylak et al [43].using ECM scaffolds for valve repair in infective endo-
carditis. In comparison, abdominal wall hernia repair
using ECM scaffolds in infected settings have shown rea-
sonable results at most, with simplified wound care and
lower rate of reoperation for matrix removal compared
to non-degradable materials [48], although the rate of
hernia recurrence remained as high a 30%. This last
point raises the question of the adequacy of a biodegrad-
able patch material for leaflet reconstruction during ac-
tive infection, as the patch will be subjected to very high
pressures while it is being remodeled. In an in vitro
comparison of the biomechanical properties of patch
materials after experimental infection with MRSA [49],
ECM scaffolds showed a significant decrease in the ul-
timate tensile strength and modulus of elasticity com-
pared to non-infected controls (see Figure 3). Taking
into account both the indirect clinical observations cited
above, and this in vitro experimental data, serious con-
cerns should be raised on the use of ECM scaffolds in
infective endocarditis, and thorough in vivo animal ex-
periments are required to evaluate the biomechanical
properties of these patch materials in this specific setting
before clinical use.Figure 3 Ultimate strength of extracellular matrix scaffolds
subjected to infection. Ultimate strength (MPa) of small intestinal
submucosa (SIS) and acellular human dermis (ADM) in response to
inoculation with MRSA. White bars and black bars represent the
control (non-inoculated) values for the 2 biologic meshes. Both
materials exhibited the greatest reduction in ultimate strength at
20 days post inoculation. *Indicates a statistically significant
difference between control groups. **Indicates a statistically
significant difference between inoculated and control groups.
Reproduced with permission from Bellows et al. [49].
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These evolving biodegradable devices, from annuloplasty
rings to patch materials, offer the potential for valve re-
pair with degradable materials replaced with autologous
tissue. This is a perfect example of translational medi-
cine, going from in vivo animal models investigating bio-
degradation and resistance to infection, to clinical
application in the hopes that these properties could fur-
ther improve the results of valve repair for infective
endocarditis. This is an evolving field with promising ex-
perimental or initial clinical results, however long-term
results are lacking and further data is necessary to valid-
ate this theoretically interesting approach to infective
endocarditis. Furthermore, given the low rate of recur-
rent endocarditis using non-degradable materials, any
study looking at these technologies, beyond the “proof
of concept” phase we are emerging from, will need a
large number of patients and rigorous follow-up to have
sufficient power to see if these new biodegradable mate-
rials can do better than conventional techniques.
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